Sea Buckthorn for Dry Eye Disease

Verdict: Weak, industry-funded evidence; eases symptoms only

Sea buckthorn oil earns only a weak evidence grade for dry eye disease: small, industry-funded trials suggest it can modestly ease subjective symptoms such as burning and redness and blunt the seasonal rise in tear-film osmolarity, but it does not reliably improve objective signs. It is an optional adjunct at best and is no substitute for artificial tears or prescription therapy.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

The grade is held down by a thin, lopsided evidence base. Every human dry-eye finding traces back to a single Finnish research group (PMID 20554904): a double-blind RCT of 86 people taking 2 g/day for 13 weeks, a secondary analysis of the same cohort, a small omega-7 pilot (n=40), and a pooled review of about 180 participants total. Benefits were consistent on patient-reported symptoms (burning, redness, OSDI) and on tear-film osmolarity, but objective measures such as tear break-up time and the Schirmer test showed no consistent improvement.

Two structural weaknesses cap confidence. All the primary trials were funded by sea buckthorn producers, triggering a high-conflict-of-interest flag, and there is little independent replication, no data beyond 12 months, and no hard quality-of-life endpoints. The samples are also too small to detect rare harms, and commercial products vary in formulation, so they may not match the doses tested.

Authorities are split but unenthusiastic. The US FDA only affirms that sea buckthorn berry products are safe (GRAS), making no efficacy claim, while EFSA went further and rejected dry-eye and tear-film health claims because cause-and-effect was not established. Among clinical bodies, only TFOS DEWS II comments, calling the evidence cautious: it acknowledges the osmolarity and symptom signal from the RCT but stresses that objective signs were unchanged and further confirmation is required. Mayo Clinic, Cleveland Clinic, Harvard Health, and the NIH Office of Dietary Supplements do not address it at all.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.39
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
72%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.393
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative;實際 E6)
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye
PMID: 20554904 2010 RCT (double-blind) n = 86
Finding: Sea buckthorn oil 2 g/day significantly attenuated the seasonal (winter) increase in tear film osmolarity vs placebo (P<0.05) and reduced symptoms of burning and redness; no significant change in Schirmer test or TBUT; treatment was well tolerated
⚠️ Industry-funded
View on PubMed
Effects of oral sea buckthorn oil on tear film fatty acids in individuals with dry eye
PMID: 21832964 2011 RCT (double-blind) n = 86
Finding: Secondary analysis of the Larmo cohort showed sea buckthorn group reported less frequent redness and burning vs placebo (P<0.05); osmolarity attenuation was driven by fatty acid composition changes (increased palmitoleic, linoleic, alpha-linolenic acid in serum)
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Based on the information provided by SBR Group, Inc. (SBR), as well as other information available to FDA, the agency has no questions at this time regarding SBR's conclusion that sea buckthorn (Hippophae rhamnoides L.) berry, berry juice, and berry puree are GRAS under the intended conditions of use. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
食品不得為醫療效能之標示、宣傳或廣告……食品標示、宣傳或廣告不得有不實、誇張或易生誤解之情形(《食品安全衛生管理法》第28條)。 source↗
L5e Specialty Society (condition-mapped)
Cautious
Oral supplementation with sea buckthorn oil (containing omega-7 palmitoleic acid as well as omega-3) has been reported in a randomized controlled trial to attenuate the increase in tear film osmolarity in winter and to reduce symptoms of redness and burning in patients with dry eye, though objective signs were not significantly altered. Further confirmation is required. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-dry-eye-INT-sea-buckthorn-001 繁體中文版 →